Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,147 | $7,080 | $5,483 | $5,583 |
| G&A Expenses | $3,430 | $4,179 | $4,663 | $5,177 |
| SG&A Expenses | $3,430 | $4,179 | $4,663 | $5,177 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,577 | $11,259 | $10,146 | $10,759 |
| Operating Income | -$9,577 | -$11,259 | -$10,146 | -$10,759 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $714 | -$651 | $512 | -$70 |
| Pre-Tax Income | -$8,864 | -$11,911 | -$9,633 | -$10,830 |
| Tax Expense | -$1 | $8 | $4 | $3 |
| Net Income | -$8,852 | -$11,909 | -$9,631 | -$10,799 |
| % Margin | – | – | – | – |
| EPS | -0.24 | -0.33 | -0.3 | -0.21 |
| % Growth | 27.3% | -10% | -42.9% | – |
| EPS Diluted | -0.26 | -0.33 | -0.3 | -0.21 |
| Weighted Avg Shares Out | 33,480 | 35,912 | 35,686 | 35,623 |
| Weighted Avg Shares Out Dil | 36,915 | 35,912 | 35,686 | 35,623 |
| Supplemental Information | – | – | – | – |
| Interest Income | $251 | $349 | $441 | $314 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $139 | $76 | $66 | $78 |
| EBITDA | -$8,725 | -$11,835 | -$9,567 | -$10,751 |
| % Margin | – | – | – | – |